The crucial role of CTLA-4 and PD-1 in regulation of a tolerogenic immune response opens up for a blockage of both checkpoint molecules that may have great therapeutic potential in terms of activating an immune response against the cancer cells. The gene discussed is CTLA4; the disease is cancer.